Information de reference pour ce titreAccession Number: | 00128378-201508000-00008.
|
Author: | Snarski, E. 1; Mank, A. 2; Iacobelli, S. 3; Hoek, J. 4; Styczynski, J. 5; Babic, A. 6; Cesaro, S. 7; Johansson, E. 8
|
Institution: | (1)Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warszawa, Poland, (2)Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands, (3)Dipartimento di Medicina dei sistemi, Universita degli Studi di Roma "Tor Vergata", Roma, Italy, (4)Data Office, European Group for Blood and Marrow Transplantation (EBMT), Leiden, Belgium, (5)Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland, (6)European Institute of Oncology, Milano, Italy, (7)Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy, (8)Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
|
Title: | |
Source: | Transplant Infectious Disease. 17(4):558-565, August 2015.
|
Abstract: | Background. Central line-associated bloodstream infection (CLABSI) is one of the most common infectious complications after hematopoietic stem cell transplantation. To prevent this complication, international guidelines recommend the implementation of the CLABSI 'prevention bundle' consisting of hand hygiene, full barrier precautions, cleaning the insertion site with chlorhexidine, avoiding femoral sites for insertion, and removing unnecessary catheters. The aim of this survey was to analyze to what extent European Group for Blood and Marrow Transplantation (EBMT) centers have included the CLABSI prevention bundle in practice.
Methods. A questionnaire used for data collection was sent to the 545 EBMT centers worldwide, 103 of which responded.
Results. All 5 components of the CLABSI prevention bundle were recorded in 28% of the centers' standard operating procedures (SOP), and 21% of the centers answered that they used all of the bundle components in clinical practice. The most common recommendation absent from the SOP was specification of all the components of full barrier precautions (43% of the centers did not include at least 1 component). Skin disinfection with chlorhexidine before catheter insertion was reported by 66% centers. CLABSI rates were monitored in 21% of centers.
Conclusions. Although most of the centers lacked 1 or more of the CLABSI prevention bundle components in their SOP, improvements could easily be made by updating the centers' SOP. The first important step is introduction of CLABSI rate monitoring in this high-risk patient population.
(C) 2015 John Wiley & Sons A/S
|
Author Keywords: | central venous catheter; CLABSI; infection prevention; HSCT; hematopoietic stem cell transplantation.
|
References: | 1. WBMT.Org. WBMT press release about reaching the 1 millionth bone marrow transplant. Available at: http://www.wbmt.org/fileadmin/pd...- ouverture dans une nouvelle fenêtre (accessed May 19, 2015).
2. Lukenbill J, Rybicki L, Sekeres MA, et al. Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant, 2013; 19 (5): 720-724.
3. Mikulska M, Del Bono V, Bruzzi P, et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection, 2012; 40 (3): 271-278.
4. Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant, 2007; 40 (1): 63-70.
5. Kim JS, Holtom P, Vigen C. Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: epidemiologic and economic consequences. Am J Infect Control, 2011; 39 (8): 640-646.
6. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant, 2009; 15 (10): 1143-1238.
7. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med, 2006; 355 (26): 2725-2732.
8. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis, 2011; 52 (9): e162-e193.
9. CVC in HSCT Questionnaire. Available at: https://emiliansnarski.files.wor...- ouverture dans une nouvelle fenêtre (accessed May 19, 2015).
10. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol, 1994; 15: 231-238.
11. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet, 1991; 338: 339-343.
12. Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit Care Med, 1996; 24: 1818-1823.
13. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med, 2002; 136: 792-801.
14. Pronovost PJ, Berenholtz SM, Needham DM. Translating evidence into practice: a model for large scale knowledge translation. BMJ, 2008; 337: a1714.
15. Sawyer M, Weeks K, Goeschel CA, et al. Using evidence, rigorous measurement, and collaboration to eliminate central catheter-associated bloodstream infections. Crit Care Med, 2010; 38: S292-S298.
16. Barsuk JH, Cohen ER, Potts S, et al. Dissemination of a simulation-based mastery learning intervention reduces central line-associated bloodstream infections. BMJ Qual Saf, 2014; 23 (9): 749-756.
17. Lugtenberg M, Burgers JS, Westert GP. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review. Qual Saf Health Care, 2009; 18: 5385-5392.
18. Fraser TG, Gordon SM. CLABSI rates in immunocompromised patients: a valuable patient centered outcome? Clin Infect Dis, 2011; 52 (12): 1446-1450.
19. Guerin K, Wagner J, Rains K, Bessesen M. Reduction in central line-associated bloodstream infections by implementation of a postinsertion care bundle. Am J Infect Control, 2010; 38 (6): 430-433.
20. Chen XX, Lo YC, Su LH, Chang CL. Investigation of the case numbers of catheter-related bloodstream infection overestimated by the central line-associated bloodstream infection surveillance definition. J Microbiol Immunol Infect, 2014. pii: S1684-1182(14)00062-0. doi: 10.1016/j.jmii.2014.03.006. [Epub ahead of print].
21. Dettenkofer M, Ebner W, Bertz H, et al. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant, 2003; 31: 795-801.
22. Dettenkofer M, Wenzler-Rottele S, Babikir R, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis, 2005; 40: 926-931.
|
Language: | English.
|
Document Type: | Original reports.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1398-2273
|
NLM Journal Code: | d1d, 100883688
|
DOI Number: | https://dx.doi.org/10.1111/tid.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|